FOA No. Title OrgRelease/Open Dates Exp. Date Activity Code(s) No. Awards Amount Comments
RFA-DA-20-025Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research (U18 - Clinical Trial Not Allowed)NIDARelease Date: 11/14/2019
Open Date: 01/13/2020
02/14/2020U18Estimate of 50 awards$150,000 directs/year
FOA-ETA-20-01The Support to Communities: Fostering Opioid Recovery Through Workforce DevelopmentNIDARelease Date: 10/31/2019
Open Date:
01/10/2020Up to $5,000,000
PAR-20-035Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)NIDA, NCI, NIAAARelease Date: 10/18/2019
Open Date: 02/17/2020
11/08/2022R61/R33Contingent upon appropriationsUp to $300,000
NOT-HS-20-001Notice of Intent to Publish Funding Opportunity Announcement to Improve the Management of Opioids and Opioid Use Disorder in Older AdultsAHRQRelease Date: 10/25/2019
Open Date:
BJA-2020-17754BJA FY 20 Harold Rogers Prescription Drug Monitoring Program (PDMP)Department of Justice Bureau of Justice AssistanceRelease Date: 03/06/2020
Open Date:
03/05/202014$2,000,000
PAR-20-118National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)NIHRelease Date: 02/25/2020
Open Date: 06/27/2020
03/26/2022U01The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.Application budgets are not limited but need to reflect the actual needs of the proposed project.
PAR-20-119National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Substance Use Disorders, or Alcohol Use Disorder (U19 Clinical Trial Optional)NIHRelease Date: 02/25/2020
Open Date: 06/27/2020
03/26/2022U19The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.Application budgets are not limited but need to reflect the actual needs of the proposed project.
BJA-2020-17106BJA FY 20 Improving Reentry for Adults with Substance Use Disorders ProgramDepartment of Justice Bureau of Justice AssistanceRelease Date: 02/26/2020
Open Date:
04/27/202014$900,000 ceiling
BJA-2020-17023BJA FY 20 Comprehensive Opioid, Stimulant, and Substance Abuse Site-based Program (COSSAP)Department of Justice Bureau of Justice AssistanceRelease Date: 02/21/2020
Open Date: 02/21/2020
05/21/2020120$6,000,000
TI-20-010State Pilot Grant Program for Treatment for Pregnant and Postpartum WomenSAMHSARelease Date: 02/19/2020
Open Date:
04/20/20205Up to $900,000
TI-20-0112020 Tribal Opioid Response grantsSAMHSARelease Date: 03/03/2020
Open Date: 03/03/2020
05/04/2020200$1,800,000
TI-20-007Services Grant Program for Residential Treatment for Pregnant and Postpartum WomenSAMHSARelease Date: 01/30/2020
Open Date: 01/30/2020
03/30/20203$1,800,000
PAR-20-092Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)NIDARelease Date: 01/24/2020
Open Date: 01/24/2020
09/02/2022UG3/UH3The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.$3M/year in directs
HRSA-20-014Opioid-Impacted Family Support ProgramRelease Date:
Open Date:
19
TI-20-006SAMHSARelease Date: 01/17/2020
Open Date: 01/17/2020
03/17/20202$850,000/year
RFA-FD-20-031Incorporating cost effectiveness & societal outcomes into FDA opioids model (U01) Clinical Trials Not AllowedFDARelease Date: 03/13/2020
Open Date: 03/16/2020
05/19/2020U01The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support.1,000,000
RFA-DA-21-001Reducing Stigma Related to Drug Use in Human Service Settings (R34 Clinical Trial Required) Department of Health and Human Services National Institutes of HealthDHHS/NIHRelease Date: 04/09/2020
Open Date:
08/11/2020R342$450,000
NOT-DA-20-044Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)DHHS/NIHRelease Date: 04/06/2020
Open Date: 05/01/2020
07/13/2020$700,000
CDC-RFA-CE20-2002Drug-Free Communities (DFC) Support Program-NewCDCRelease Date: 02/18/2020
Open Date:
06/08/2020200$125,000
I-20-013Treatment, Recovery, and Workforce Support GrantSAMHSARelease Date: 03/31/2020
Open Date:
06/01/20208$500,000
NOT-MD-20-019Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health DisparitiesNIMHD, NIA, NIMHRelease Date: 04/10/2020
Open Date: 05/01/2020
05/01/2021P20125,000
PA-20-208Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional)NIDARelease Date: 05/16/2020
Open Date: 05/16/2020
05/23/2023R36Contingent upon meritorious applicationsNo more than $50,000/year
PAR-20-182Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)NIDARelease Date: 05/04/2020
Open Date: 09/30/2020
10/31/2020R011-3Less than $1M/year for upt ot 5 years
CDC-RFA-CE20-2002Drug-Free Communities (DFC) Support Program-New Department of Health and Human Services Centers for Disease Control - NCIPCCDCRelease Date: 02/18/2020
Open Date: 02/18/2020
06/08/2020200$125,000
PAR-20-224Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)Release Date: 06/01/2020
Open Date: 07/13/2020
08/16/2020DP2$375,000
PAR-20-225Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)Release Date: 06/01/2020
Open Date: 09/19/2020
10/20/2022DP1Contingent upon appropriations$300,000
PAR-20-241Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)NIDARelease Date: 06/24/2020
Open Date: 09/30/2020
10/31/2020R011-3$1M
RFA-DA-21-024PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)NIDA/NIAIDRelease Date: 06/29/2020
Open Date: 10/12/2020
11/13/2020R012-3$2.5M over 5 years
PAR-20-249NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NIDARelease Date: 07/01/2020
Open Date: 02/01/2021
11/16/2023K12Contingent upon NIH appropriations$500K/year
Systems for Action: Supplemental Research on COVID-19 Response and RecoveryRobert Wood Johnson FoundationRelease Date:
Open Date:
08/05/2020Foundation5Up to $100K/year
PAR-20-237Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)Release Date: 06/17/2020
Open Date: 07/28/2020
12/02/2020R01Contingent upon NIH appropriations$500,000/year
RFA-DA-21-024PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)NIDA, NIAIDRelease Date: 06/29/2020
Open Date: 10/12/2020
11/13/2020R012-3Not limited
PAR-20-279Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)NIDA/NIAAARelease Date: 07/27/2020
Open Date: 11/15/2020
08/11/2023UG3/UH3Contingent upon meritorious applications$500K per year
PAR-20-267NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)NIDARelease Date: 07/17/2020
Open Date: 08/25/2020
11/18/2022P30Contingent upon meritorious applicationsNot limited
PAR-20-249NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NIDARelease Date: 07/01/2020
Open Date: 02/01/2021
11/16/2023K12Contingent upon meritorious applications$500K per year
HRSA-21-088Rural Communities Opioid Response Program – ImplementationHRSARelease Date: 09/04/2020
Open Date:
7878M total program
SP-19-006Drug-Free Communities (DFC) Support Program-Competing ContinuationDFCRelease Date:
Open Date:
SP-19-005Drug-Free Communities (DFC) Support Program-NewDFCRelease Date:
Open Date:
RFA-DA-20-019Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed)NIDARelease Date: 05/30/2019
Open Date: 09/17/2019
R61/R335Up to $300K
PA-FPR-19-001FORECASTED: Availability of funds for Title X Family Planning– Innovations in Family Planning Clinical Service Delivery and Studies to Address Opportunities and Barriers for Linking Family Planning Services and Substance Use Disorder Screening and TreatmentDHHS/OASHRelease Date:
Open Date:
10$400K
HHS-2019-ACF-ACYF-CU-1568Regional Partnership Grants to Improve Well-Being and Permanency Outcomes for Children and Families Affected by Opioids and Other Substance AbuseDHHSRelease Date:
Open Date:
7Up to $2.65M
BJA-2019-15111BJA FY 19 Comprehensive Opioid Abuse Site-based ProgramDOJRelease Date: 04/05/2019
Open Date:
150Up to $5M
BAA-DAIT-75N93019R00009Development of Vaccines for the Treatment of Opioid Use DisorderNIAIDRelease Date: 03/05/2019
Open Date:
$2-3M/year
NOT-DA-19-048Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and AddictionRelease Date:
Open Date:
NOT-DA-19-041Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse ResearchRelease Date:
Open Date:
NOT-DA-19-38Notice of Special Interest (NOSI): Gene-Environment Interplay in Substance Use Disorders (R01, R21)Release Date:
Open Date:
NOT-DA-19-037Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)Release Date:
Open Date:
NOT-DA-19-035Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)NIDARelease Date:
Open Date:
PAR-19-282Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)NIDARelease Date: 05/15/2019
Open Date: 09/10/2019
05/08/2023R61/R33ContingentSee announcement
PAR-19-207Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)NIAAA/NIDARelease Date: 03/04/2019
Open Date: 04/25/2019
09/08/2022R25not limitedNot limited
PAR-19-207Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)NIAAA/NIDARelease Date: 03/04/2019
Open Date: 04/25/2019
09/08/2022R01Not limited
PAR-19-327Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)NIDARelease Date: 08/01/2019
Open Date: 07/26/2019
09/02/2022U01three to fourUp to $5M/year
PAR-19-318Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01Clinical Trial Optional)NIDARelease Date: 07/26/2019
Open Date: 08/26/2019
09/02/2022R01ContingentUp to $3M/year
PA-19-201Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)NIHRelease Date: 02/28/2019
Open Date: 05/16/2019
07/08/2022R21$275K/2 years
PA-19-200Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)NIHRelease Date: 02/28/2019
Open Date: 05/05/2019
07/08/2022R01Not limited
PA-18-946Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/16/2018
01/08/2022R21$275K for 2 years
PA-18-945Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/05/2019
01/08/2022R01Not limited
PA-18-944Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/05/2018
01/08/2022R01Not limited
PA-18-943Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/16/2018
01/08/2022R21$275K for 2 years
NOT-DA-19-066Notice of Special Interest (NOSI): Epidemiology of Drug AbuseNIDARelease Date: 08/29/2019
Open Date: 10/05/2019
01/08/2022
PAR-19-278Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)NIDARelease Date: 05/08/2019
Open Date: 05/24/2019
12/18/2021R21/R33R21 - Not to exceed $125K/year. R33-Not to exceed $250K
PAR-19-100Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)NCATSRelease Date: 12/12/2018
Open Date: 02/08/2019
11/10/2021R21Not to exceed $200K
PAR-19-099Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award, (U01 Clinical Trial Optional)NCATSRelease Date: 12/12/2018
Open Date: 02/08/2019
11/10/2021U01Clinical not to exceed $750K. Non-clinical not to exceed $400K
PAR-19-064Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)NIDARelease Date: 11/09/2019
Open Date: 01/08/2019
11/09/2021R21$275K for 2 years
PAR-19-223Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)NIDARelease Date: 03/18/2019
Open Date: 09/21/2019
10/20/2021$up to 300K for up to 5 years
RFA-DA-19-020HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 - Clinical Trial Optional)NIDARelease Date: 12/10/2018
Open Date: 01/10/2019
09/09/2021R41/R423 to 10Total $3M FY2019
RFA-DA-19-019HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional)NIDARelease Date: 12/10/2018
Open Date: 12/10/2018
09/09/2021R43/R4410 to 30Total $7M FY2019
RFA-NS-19-018HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)NINDSRelease Date: 12/10/2018
Open Date: 12/10/2018
02/23/2021UH33 to 4Total $3M
RFA-NS-19-017HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)NINDSRelease Date: 12/10/2018
Open Date: 12/10/2018
02/23/2021U444 to 8Not to exceed $1M/year in Phase 1
RFA-NS-19-016HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)NINDSRelease Date: 12/10/2018
Open Date: 12/09/2018
02/23/2021UG3/UH33 to 6Total $4M
RFA-EB-18-003HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)NIBIBRelease Date: 12/10/2018
Open Date: 01/08/2019
02/23/2021U185 to 10Not to exceed $500K
PA-18-591Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)NIHRelease Date: 01/25/2018
Open Date: 01/25/2018
01/26/2021
PAR-18-747Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional)NIMHDRelease Date: 04/10/2018
Open Date: 05/15/2018
11/14/2020R01Not limited
PAR-18-745Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)NIMHDRelease Date: 04/10/2018
Open Date: 05/15/2018
11/14/2020R21$275K for 2 years
PAS-18-625Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)NIDARelease Date: 02/02/2018
Open Date: 05/16/2018
09/08/2020R213 to 5Total $2M for FY2019
PAS-18-625Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)NIDARelease Date: 02/02/2018
Open Date: 05/16/2018
09/08/2020R213 to 5$275K total project
PAR-18-746NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NIDARelease Date: 04/06/2018
Open Date: 05/11/2018
08/29/2020K12$500K Direct costs/year
RFA-DA-18-022Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01  Clinical Trial Optional)NIDARelease Date: 03/14/2018
Open Date: 07/22/2018
08/22/2020R013 to 4
RFA-DA-18-020NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)NIDARelease Date: 12/06/2018
Open Date: 06/25/2019
07/26/2020UG3/UH3Up to 2/yearTotal $2M FY2019
PA-18-079Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional)NIDA/NIARelease Date: 11/03/2017
Open Date: 01/17/2018
05/08/2020R21$275K for 2 years
PA-18-061Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional)NIDA/NIARelease Date: 11/03/2017
Open Date: 01/06/2018
05/08/2020R01Not limited
PA-17-157Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21)NIDARelease Date: 02/08/2017
Open Date: 05/16/2017
05/08/2020R21$275K for 2 years
PA-17-155Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01)NIDARelease Date: 02/08/2017
Open Date: 05/05/2017
05/08/2020R01Not limited
PA-17-134Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03)NIAAARelease Date: 01/25/2017
Open Date: 05/16/2017
05/08/2020R03$50K/year
PA-17-132Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21)NIAAARelease Date: 01/25/2017
Open Date: 05/16/2017
05/08/2020R21$275K for 2 years
HRSA-20-031Rural Communities Opiod Response Program - ImplementationHRSARelease Date: 05/13/2019
Open Date:
05/26/202079$79M program
RFA-NS-18-046Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)NINDSRelease Date: 09/19/2018
Open Date: 10/27/2018
03/13/2020R61/R338 to 10Not limited
RFA-NS-18-041Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)NINDSRelease Date: 08/02/2018
Open Date: 10/27/2018
03/13/2020R61/R338 to 10Not limited
RFA-DA-19-002Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)NIDARelease Date: 12/14/2017
Open Date: 01/25/2018
02/23/2020UG3/UH33 to 4Total $10M/Fiscal year
PA-18-078Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)NIDARelease Date: 11/03/2017
Open Date: 01/17/2018
01/08/2020R21$275K for 2 years
PA-17-120Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01)NIDARelease Date: 01/10/2017
Open Date: 01/10/2017
01/08/2020R01Not limited
HRSA-20-106Rural Communities Opioid Response Program – Neonatal Abstinence Syndrome (RCORP-NAS)Department of Health and Human Services Health Resources and Services AdministrationRelease Date: 02/06/2020
Open Date: 02/06/2020
04/14/202030

Estimated Total Program Funding:
$15,000,000

FOR-FD-20-008FOR-FD-20-008Food and Drug AdministrationRelease Date:
Open Date: 03/06/2020

Forecasted

HHS-2020-IHS-COIPP-0001Community Opioid Intervention Pilot ProjectDepartment of Health and Human ServicesRelease Date: 02/14/2020
Open Date:

Forecasted

HRSA-21-091Rural Communities Opioid Response Program – Psychostimulant SupportHRSARelease Date: 01/06/2021
Open Date:
15$7.5M Total program

Forecasted

Strengthening Access to Care for Opioid Use Disorder Patients During the COVID-19 National Public Health Emergency: Recovery Support ServicesFORERelease Date: 05/22/2020
Open Date: 05/22/2020
07/31/2020FoundationContingent upon NIH appropriations$25K-$75K

https://forefdn.org/wp-content/uploads/2020/05/COVID19_RFP_FINAL_5-22-2020.pdf

NOT-TR-20-025NCATS Announces Plans to Publish the ASPIRE 2020 Reduction-to-Practice Challenge Prize CompetitionNCATSRelease Date: 08/26/2020
Open Date:

In this Reduction-to-Practice Challenge, the second phase of the initiative, NCATS aims to build upon the designs from the Design Challenges and reward the development of a working prototype of a comprehensive integrated platform, culminating in the development of better, more effective and non-addictive analgesics. It is anticipated that this Challenge would require large, multi-expert teams. These teams may be assembled from the innovators from the 2018 Design Challenge areas and others who did not participate in the 2018 Design Challenges. This Notice alerts the scientific community that NCATS intends to hold a three-stage prize open competition for the NCATS ASPIRE Reduction-to-Practice Challenge, the stages are 1) planning, 2) prototype development and milestones delivery, and 3) prototype delivery and validation and testing. It is anticipated that the announcement will be published in September 2020, with the submission window for Stage 1 planning solutions from late November through the end of February 2021.

RFA-HL-20-031HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed) Department of Health and Human ServicesNIHRelease Date: 01/24/2020
Open Date: 01/24/2020
03/24/2020R61/R33

NHLBI intends to commit total costs of up to $7,000,000 in FY2020-2021 to fund up to 10Phase I (R61) awards.

NHLBI intends to commit total costs of up to $3,000,000 per year in FY2022-2024 to fund up to 5 Phase II (R33) awards.

NOT-DA-20-071Rural Communities Opioid Response Program – Psychostimulant SupportHRSARelease Date: 11/01/2020
Open Date:
3

Notice

The National Institute on Health (NIH) intends to publish two Funding Opportunity Announcements (FOA) to solicit applications to build a network of researchers to develop sustainable evidence-based interventions to effectively treat non-cancer chronic pain (CP) and opioid use disorder (OUD). This network will be part of the of the NIH’s Helping to End Addiction Long-term (HEAL)SM Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and opioid use disorder and (2) enhance pain management.
The purpose of this notice is to allow potential applicants sufficient time to develop meaningful collaborations and projects. This FOA is expected to use a collaborative program grant mechanism (RM1). The FOA is expected to be published in November 2020 with an expected application due date in January/February 2021.

PAR-20-221NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)NIDARelease Date: 06/01/2020
Open Date: 07/13/2020
08/16/2022DP12-3 awards/year$700,000

Reissue of RFA-DA-18-019

 FOA No. Title OrgRelease/Open Dates Exp. Date Activity Code(s) No. Awards Amount Comments